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Background: O6-methylguanine DNA methyltransferase (MGMT ) silenc-
ing by promoter methylation is a common alteration found in different cancer
types. This has been shown to be both a prognostic and a predictive
marker of sensitivity to alkylating agent-based therapy like dacarbazine
and temozolomide in glioblastoma. However in other malignancies its
value remains controversial. This might be due to sampling issues, tumor
heterogeneity or to the use of inadequate detection methods. In this study,
we present a new assay to reliably measure MGMT methylation both in
tumor and plasma samples.
Material and Methods: Methylation of MGMT has been assessed
by an ultra-sensitive digital PCR technique, in which a two-step PCR
is followed by detection via fluorocytometer (Methyl-BEAMing). Results
were compared to two other commonly used techniques (Methylation
Specific PCR, MSP and pyrosequencing). Two samples datasets have
been evaluated: tumors from a cohort of 98 newly diagnosed glioblastoma
patients from the pre-temozolomide era, and specimens from a cohort of 68
metastatic colorectal cancer patients treated with dacarbazine in a phase II
clinical trial (DETECT-01 trial, EUDRACT number 2011–002080−21). The
prognostic and/or predictive value of MGMT methylation has also been
evaluated. As a proof of concept, the three methods were assessed in a
subset of colorectal cancer patients’ plasma derived DNA to evaluate their
performance as a liquid biopsy test.
Results: Methyl-BEAMing showed high reproducibility across independent
experiments, as well as high sensitivity (up to 0.09% methylation detected)
and specificity. In the glioblastoma cohort, Methyl-BEAMing methylated
status (>50%) was associated with a decreased hazard ratio for death
(HR = 0.35; p < 0.0001) compared to MSP (HR = 0.54; p = 0.006) or
pyrosequencing (HR = 0.61; p = 0.059). In mCRC, tissue where tumor
heterogeneity is possibly higher, both Methyl-Beaming and pyrosequecing
assays provided better prediction of objective response to dacarbazine
than MSP. Progression free survival was also improved in metastatic
colorectal cancer with methylated status when samples were assessed with
Methyl-BEAMing (p = 0.0012) or pyrosequencing (p = 0.0005). Quantitative
evaluation of MGMT methylation in circulating tumor DNA was effective
with Methyl-BEAMing.
Conclusions: MGMT methylation testing based on BEAMing technology
outperforms commonly used methods and might allow the non-invasive
follow-up of patients, upon alkylating agent treatments using blood
circulating DNA.
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Low, frequent doses of PM060184 induce remarkable in vivo
antitumor activity
P. Aviles1, M.J. Guillen1, P.P. Lopez-Casas2, F. Sarno3, O. Catalun˜a4,
P. Nun˜ez4, C. Cuevas4, M. Hidalgo3. 1PharmaMar S.A., Preclinical,
Colmenar Viejo (Madrid), Spain; 2Centro Nacional de Investigaciones
Oncolo´gicas and Hospital de Madrid, Colmenar Viejo (Madrid), Spain;
3Centro Nacional de Investigaciones Oncolo´gicas and Hospital de
Madrid, Madrid, Spain; 4Pharmamar S.A., Preclı´nica, Colmenar Viejo
(Madrid), Spain
Background: PM060184 is a synthetic marine-derived compound origi-
nally isolated from the marine sponge Lithoplocamia lithistoides. PM060184
induces disorganization and disruption of the microtubule network as
well as aberrant mitotic spindle multipolarization and chromosome
missegregation. These effects give rise to prometaphase arrest and
formation of multinucleated cells. Then, cells enter to caspase-driven
apoptosis or are arrested in a pseudo-senescent state. PM060184 is
currently under evaluation in Phase I clinical studies in patients with
advanced cancer diseases. The objective of the present work was to
explore the in vivo anticancer efficacy of PM060184 administered at low
daily doses (0.5 to 2mg/kg).
Material and Methods: Athymic female nu/nu mice were subcutaneously
implanted with different tumors: MDA-MB-231 (breast), H460 (NSCLC)
and several pancreas patient-derived (AVATAR) tumors, namely JH-
010, JH-015, Panc-291, and Panc-039. Tumor (ca. 300mm3) bearing
animals (N = 6−10/group) were randomly allocated to receive PM060184
or placebo. Treatments (0.5 to 2mg/kg, iv) were administered daily for
20 consecutive days. Antitumor effect was calculated using DT/DC (%),
defined as a percentage of the change in tumor size for treated (T) and
placebo (C) groups during the placebo-treated survival time (D). Complete
tumor regression (CR) was defined when tumor volume <63mm3 for 2 or
more consecutive measurements.
Results: The treatment with PM060184 produced lowest DT/DC values as







Breast MDA-MB-231 2.0 7.3 21
1.0 14.1 21
0.5 24.0 21
NSCLC H460 2.0 5.5 11
1.0 7.8 11
0.5 17.7 11
Pancreas JH-024 2.0 19.7 21
JH-010 2.0 14.8 21
JH-015 2.0 38.9 28
Panc-291 2.0 12.0 24
Panc-039 2.0 6.1 28
Conclusion: The treatment with PM060184 at low, frequently given doses
demonstrated significant in vivo antitumor activity in breast, NSCLC and
pancreas xenografted tumors.
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Background: Brain metastases are found in about 10% of lung cancer
patients at the time of diagnosis, and about 40% of all lung cancer
patients develop brain metastases during their disease progression. The
chemotherapy is limited because of little or no effectiveness due to the
blood–brain barrier. The radiation therapy is the most frequently used, and
sensitizing agents, which synergize with radiation, can improve the efficacy
of the therapy.
Material and Methods: Sodium metaarsenite (KML001®) is an orally
bioavailable arsenic compound that has entered phase I/II clinical trials in
solid tumors and hematopoietic malignancies. In this study, we elucidated
the radio-sensitizing effect of sodium metaarsenite (KML001®) in an animal
model of metastasis of lung cancer to the brain.
Results: The clonogenic assay showed that treatment with sodium
metaarsenite (KML001®) inhibited clone formation in radio-sensitive
(H23) and radio-resistant lung cancer cells (A549 and PC14PE6) in a
concentration-dependent manner. The combined irradiation and sodium
metaarsenite (KML001®) treatment significantly reduced colony formation
in H23 (p < 0.01), A549 (p < 0.05) and PC14PE6 lung cancer cells
(p < 0.05), compared with the radiation alone group.
In the metastatic brain cancer model with H23 cells, sodium metaarsenite
(KML001®) treatment (5mg/kg/day) and radiation therapy (5 Gy) showed
54.5% and 67.6% reduction in tumor volume, respectively, compared with
control group (p < 0.001 vs. control). The combined irradiation and sodium
metaarsenite (KML001®) treatment induced 88.1% decrease in tumor
volume (p < 0.001 vs. control).
In the metastatic brain cancer model with PC14PE6 cells, the single
irradiation (15 Gy) and the combined irradiation (15 Gy) and sodium
metaarsenite (KML001®) treatment (7mg/kg/day) significantly increased
median survival day of the mice to 22 and 26 days, respectively, compared
to control group (median survival day = 19) (p < 0.001). The combination
improved survival significantly with regard to the radiation only group
(p < 0.001).
Conclusions: This study demonstrated that sodium metaarsenite
(KML001®) may have potential as an alternative therapeutic agent,
